Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
DRD1 1812 CABERGOLINE CHEMBL1201087 agonist GuideToPharmacologyInteractions, DrugBank 10641988, 18691132, 11436517, 16982285, 12388666
DRD1 1812 CLOZAPINE CHEMBL42 antagonist PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 11752352
DRD1 1812 LISURIDE CHEMBL157138 agonist, antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 17139284, 17016423, 18691132
DRD1 1812 MINAPRINE CHEMBL278819 agonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
DRD1 1812 ACETOPHENAZINE CHEMBL1085 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
DRD1 1812 NORADRENALINE CHEMBL1356607 agonist GuideToPharmacologyInteractions
DRD1 1812 NICKEL (II) ION CHEMBL56175 agonist GuideToPharmacologyInteractions
DRD1 1812 PERGOLIDE CHEMBL531 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
DRD1 1812 ROTIGOTINE CHEMBL1303 agonist GuideToPharmacologyInteractions, TEND, DrugBank 18691132
DRD1 1812 CHLORPROMAZINE CHEMBL71 antagonist GuideToPharmacologyInteractions
DRD1 1812 FLUPHENAZINE CHEMBL726 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
DRD1 1812 MESORIDAZINE CHEMBL1088 antagonist GuideToPharmacologyInteractions
DRD1 1812 NITRIC OXIDE CHEMBL1200689 antagonist GuideToPharmacologyInteractions
DRD1 1812 CHLORPROTHIXENE CHEMBL908 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423, 1830565
DRD1 1812 PALIPERIDONE CHEMBL1621 antagonist DrugBank 7531353, 7520908
DRD1 1812 PIPOTIAZINE CHEMBL398880 antagonist DrugBank 7918347
DRD1 1812 THIOPROPERAZINE CHEMBL609109 antagonist DrugBank 7918347
DRD1 1812 FENOLDOPAM MESYLATE CHEMBL1026 agonist ChemblInteractions
DRD1 1812 MELEVODOPA CHEMBL1328898 TdgClinicalTrial
DRD1 1812 ETILEVODOPA CHEMBL1823681 TdgClinicalTrial
DRD1 1812 ARIPIPRAZOLE CHEMBL1112 partial agonist, antagonist DrugBank 17848919
DRD1 1812 ROPINIROLE CHEMBL589 agonist DrugBank 18691132
DRD1 1812 ERGOTAMINE CHEMBL442 agonist DrugBank 12525272
DRD1 1812 APOMORPHINE CHEMBL53 agonist GuideToPharmacologyInteractions, TEND, DrugBank 11752352, 10641988, 18691132, 12453049
DRD1 1812 RISPERIDONE CHEMBL85 antagonist DrugBank 15992090, 7520908
DRD1 1812 PROPIOMAZINE CHEMBL1201210 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
DRD1 1812 CHEMBL520992 CHEMBL520992 agonist GuideToPharmacologyInteractions
DRD1 1812 CHEMBL26736 CHEMBL26736 agonist GuideToPharmacologyInteractions
DRD1 1812 SCH-23390 CHEMBL62 antagonist GuideToPharmacologyInteractions
DRD1 1812 CHEMBL324017 CHEMBL324017 antagonist GuideToPharmacologyInteractions
DRD1 1812 SPIPERONE CHEMBL267930 antagonist GuideToPharmacologyInteractions
DRD1 1812 ZUCLOPENTHIXOL CHEMBL87385 antagonist TdgClinicalTrial, TEND, DrugBank 1822319, 10222441
DRD1 1812 MIANSERIN CHEMBL6437 binder DrugBank
DRD1 1812 METHYLERGONOVINE CHEMBL1201356 antagonist TdgClinicalTrial, TEND, TTD
DRD1 1812 ASENAPINE (CHEMBL3187365) CHEMBL3187365 TdgClinicalTrial
DRD1 1812 PERGOLIDE MESYLATE CHEMBL1275 agonist ChemblInteractions
DRD1 1812 PHENYLPROPANOLAMINE CHEMBL61006 partial agonist DrugBank 12873745
DRD1 1812 TRIFLUPROMAZINE CHEMBL570 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
DRD1 1812 ERGOLOID MESYLATES CHEMBL2311030 agonist, antagonist ChemblInteractions, DrugBank 8786706, 1606351, 10084415, 2869188
DRD1 1812 ACEPROMAZINE CHEMBL39560 agonist, antagonist GuideToPharmacologyInteractions, DrugBank 7918347
DRD1 1812 CHEMBL291143 CHEMBL291143 agonist GuideToPharmacologyInteractions
DRD1 1812 SEROTONIN CHEMBL39 agonist GuideToPharmacologyInteractions
DRD1 1812 BROMOCRIPTINE CHEMBL493 agonist GuideToPharmacologyInteractions
DRD1 1812 SKF-38393 CHEMBL286080 agonist GuideToPharmacologyInteractions
DRD1 1812 CHEMBL1255588 CHEMBL1255588 antagonist GuideToPharmacologyInteractions
DRD1 1812 HALOPERIDOL CHEMBL54 antagonist GuideToPharmacologyInteractions
DRD1 1812 PERICIAZINE CHEMBL251940 antagonist GuideToPharmacologyInteractions, DrugBank 7918347
DRD1 1812 LEVOMEPROMAZINE CHEMBL1764 antagonist DrugBank 15701205
DRD1 1812 THIOTHIXENE CHEMBL1201 antagonist DrugBank 7918347, 3039860
DRD1 1812 METHYLERGONOVINE MALEATE CHEMBL1200843 antagonist ChemblInteractions
DRD1 1812 QUETIAPINE CHEMBL716 TEND
DRD1 1812 OLANZAPINE CHEMBL715 antagonist TdgClinicalTrial, TEND, DrugBank 11752352, 17848919, 10227113, 15771415, 18308814
DRD1 1812 THIETHYLPERAZINE CHEMBL1378 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
DRD1 1812 LOXAPINE CHEMBL831 antagonist, binder TEND, DrugBank 11752352
DRD1 1812 PROMAZINE CHEMBL564 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
DRD1 1812 FENOLDOPAM CHEMBL588 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 19293728, 11752352, 8103596
DRD1 1812 FLUPENTIXOL CHEMBL54661 antagonist GuideToPharmacologyInteractions, DrugBank 10531405, 17139284, 17016423, 17111172
DRD1 1812 CARPHENAZINE CHEMBL1201328 antagonist TdgClinicalTrial, TEND, DrugBank 4887393, 4861216, 4889058
DRD1 1812 DOPAMINE CHEMBL59 agonist GuideToPharmacologyInteractions
DRD1 1812 NIACIN CHEMBL573 agonist GuideToPharmacologyInteractions
DRD1 1812 PALMITIC ACID CHEMBL82293 agonist GuideToPharmacologyInteractions
DRD1 1812 ECOPIPAM CHEMBL298406 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions
DRD1 1812 KETANSERIN CHEMBL51 antagonist GuideToPharmacologyInteractions
DRD1 1812 PROCHLORPERAZINE CHEMBL728 antagonist GuideToPharmacologyInteractions, TEND
DRD1 1812 CHEMBL13668 CHEMBL13668 antagonist GuideToPharmacologyInteractions
DRD1 1812 THIORIDAZINE CHEMBL479 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
DRD1 1812 DROTRECOGIN ALFA (ACTIVATED) CHEMBL2109065 PharmGKB
DRD1 1812 COCAINE CHEMBL370805 TEND
DRD1 1812 E-FLUPENTIXOL CHEMBL42055 TdgClinicalTrial, TEND
DRD1 1812 BUPROPION CHEMBL894 PharmGKB
DRD1 1812 PIMOZIDE CHEMBL1423 antagonist ChemblInteractions
DRD1 1812 AMOXAPINE CHEMBL1113 antagonist ChemblInteractions, DrugBank 11180191
DRD1 1812 CINNARIZINE CHEMBL43064 binder DrugBank 11180191
DRD1 1812 PERPHENAZINE CHEMBL567 antagonist TdgClinicalTrial, TEND, DrugBank 2573104, 17455212
DRD1 1812 MIRTAZAPINE CHEMBL654 binder DrugBank 15771415, 8930006, 3419539
DRD1 1812 LEVODOPA CHEMBL1009 agonist TdgClinicalTrial, TEND, DrugBank 11978145, 18549347, 9633680
DRD1 1812 ILOPERIDONE CHEMBL14376 antagonist TdgClinicalTrial, DrugBank 23272794

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
DRD1 rs5326 CT + TT methylphenidate efficacy yes Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002). Please note that alleles have been complemented to the plus chromosomal strand. Genotypes CT + TT are associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC. 23856854 1184510511
DRD1 rs4867798 CC + CT methylphenidate efficacy yes Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002). Please note that alleles have been complemented to the plus chromosomal strand. Genotypes CC + CT is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype TT. 23856854 1184510516
DRD1 rs686 A clozapine efficacy no Frequencies entered for "cases" vs. "controls" are for responders vs. nonresponders. Allele A is not associated with response to clozapine in people with Schizophrenia as compared to allele G. 17092969 982025903
DRD1 rs4532 C lithium efficacy not stated This is from a review article which does not give all the details. It does not state exactly how the alleles were compared. Allele C is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele T. 21047205 699639199
DRD1 rs265981 A lithium dosage not stated This is from a review article which does not give all the details. It says that no association was found between the SNP and lithium response, but it does not state exactly how the alleles were compared. Allele A is not associated with response to lithium in people with Bipolar Disorder as compared to allele G. 21047205 699639210
DRD1 rs686 G clozapine efficacy yes This association was found in carriers of the DRD3 rs6280 AA genotype (gene-gene interaction analysis). Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A. 21332319 827793107
DRD1 rs4532 CC methadone dosage no Please note that alleles have been complemented to the positive strand. Genotype CC is not associated with dose of methadone in people with Substance-Related Disorders as compared to genotypes CT + TT. 18687376 1449271149
DRD1 rs265981 A clozapine efficacy no Frequencies entered for "cases" vs. "controls" are for responders vs. nonresponders. Allele A is not associated with response to clozapine in people with Schizophrenia as compared to allele G. 17092969 982025895
DRD1 rs5326 C risperidone efficacy no No significant differences in genotype or allele frequencies were observed between responders and non-responders. Patients were either part of the Shanghai (n=97) or Henan (n=88) cohorts. Response based on a cut-off of 50% in terms of corrected percent change of Positive and Negative Syndrome Scale (PANSS). Patients treated with risperidone monotherapy for 4 weeks. Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T. 25179995 1445296525
DRD1 rs4867798 C risperidone efficacy no No significant differences in genotype or allele frequencies were observed between responders and non-responders. Patients were either part of the Shanghai (n=97) or Henan (n=88) cohorts. Response based on a cut-off of 50% in terms of corrected percent change of Positive and Negative Syndrome Scale (PANSS). Patients treated with risperidone monotherapy for 4 weeks. Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T. 25179995 1445296532
DRD1 rs4532 C clozapine efficacy no It was pointed out that this was a failure to replicate a finding by Potkin et al. (2003) (PMID:12556915), which was a functional study at the subject level, but that there was a trend in the same direction as the results from that small study. This dataset included those subjects. Frequencies entered for "cases" vs. "controls" are for responders vs. nonresponders. Allele C is not associated with response to clozapine in people with Schizophrenia as compared to allele T. 17092969 982025774
DRD1 rs4532 C risperidone efficacy no No significant differences in genotype or allele frequencies were observed between responders and non-responders. Patients were either part of the Shanghai (n=97) or Henan (n=88) cohorts. Response based on a cut-off of 50% in terms of corrected percent change of Positive and Negative Syndrome Scale (PANSS). Patients treated with risperidone monotherapy for 4 weeks. Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T. 25179995 1445296539
DRD1 rs4532 CC + CT antipsychotics efficacy no Patients' psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). Drugs prescribed were clozapine (58 patients), risperidone (28 patients), aripiprazole (25 patients), quetiapine (18 patients), olanzapine (12 patients), paliperidone (3 patients), ziprasidone (1 patient), fluphenazine (21 patients), zuclopenthixol (19 patients), amisulpride (13 patients), flupentixol (9 patients), promazine (7 patients), and haloperidol (3 patients). Genotypes CC + CT are not associated with response to antipsychotics in people with Schizophrenia as compared to genotype TT. 27287786 1448258537
DRD1 rs4532 CC methadone efficacy no Please note that alleles have been complemented to the positive strand. Genotype CC is not associated with response to methadone in people with Substance-Related Disorders as compared to genotypes CT + TT. 18687376 1449271168
DRD1 rs5326 CC + TT antipsychotics efficacy no Alleles given as A and G. Patients' psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). Drugs prescribed were clozapine (58 patients), risperidone (28 patients), aripiprazole (25 patients), quetiapine (18 patients), olanzapine (12 patients), paliperidone (3 patients), ziprasidone (1 patient), fluphenazine (21 patients), zuclopenthixol (19 patients), amisulpride (13 patients), flupentixol (9 patients), promazine (7 patients), and haloperidol (3 patients). Genotypes CC + TT are not associated with response to antipsychotics in people with Schizophrenia as compared to genotype CC. 27287786 1448258544
DRD1 rs265976 GT clozapine efficacy yes The GT group improved the least compared to either the GG or the TT group. This is not significant after correction for multiple testing, but the authors state that it's not clear that this correction should be done, and that this is significant but exploratory and should be confirmed in a larger study. The association was found in African Americans but not in the Caucasian sample. Frequencies entered for "cases" vs. "controls" are for responders vs. nonresponders. Genotype GT is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes GG + TT. 17092969 982025734